Please assess the completion status of the following clinical trial:

Trial Title: Imatinib Mesylate (Gleevec) and Paclitaxel in Recurrent Patients of Ovarian and Other Cancers of Mullerian Origin

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients at least 18 years of age.~* Histologically documented diagnosis of epithelial carcinoma arising in the ovary, fallopian tube or peritoneum, of any stage or grade at diagnosis. \*Patients must have received initial cytoreductive surgery and chemotherapy with at least one platinum based chemotherapy regimen.~  \*Eligible platinum resistant patients will have failed no more than two additional non platinum cytotoxic regimens for their persistent or recurrent disease.~* Measurable disease.~* Performance status 0, 1, 2 (Eastern Cooperative Oncology Group) .~* Adequate end organ function, defined as the following: total bilirubin \< 1.5 x upper limit of normal (ULN), SGOT and SGPT \< 2.5 x UNL, creatinine \< 1.5 x ULN, ANC \> 1.0 x 10E9/L, platelets \> 100 x 10E9/L.~* Written, voluntary informed consent.~Exclusion Criteria:~* Patient has received any other anticancer treatment within 21 days of first day of study drug dosing and shown recovery of any recent drug-induced neutropenia and thrombocytopenia.~* Patient has another primary malignancy that has required active intervention within 5 years, with the exception of basal cell skin cancer or a cervical carcinoma in situ.~* Patient with Grade III/IV cardiac problems as defined by the New York Heart Association Criteria (i.e., congestive heart failure, myocardial infarction within 6 months of study).~* Patient has a severe and/or uncontrolled medical disease (i.e., uncontrolled diabetes, chronic renal disease, or active uncontrolled infection).~* Patients on coumadin-derived anticoagulants.~* Patient with brain metastasis.~* Chronic liver disease, Hep B or C.~* Patient has a known diagnosis of human immunodeficiency virus (HIV) infection.~* Patient received chemotherapy within 3 weeks -unless the disease is rapidly progressing.~* Patient previously received radiotherapy to at least 25 % of the bone marrow.~* Patient had a major surgery within 2 weeks prior to study entry.~* Patient with any significant history of non-compliance to medical regimens or with inability to grant reliable informed consent.~* Patient is on any drug that may interfere with Gleevec (e.g., Dilantin, Coumadin,or others on the list on page 33-37 of the protocol).

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Paclitaxel + Imatinib Mesylate (Gleevec) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).